Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

  • Sandro Pignata
  • , Michael Bookman
  • , Jalid Sehouli
  • , Austin Miller
  • , Richard T. Penson
  • , Cagatay Taskiran
  • , Charles Anderson
  • , Sakari Hietanen
  • , Tashanna Myers
  • , Radoslaw Madry
  • , Lyndsay Willmott
  • , Alain Lortholary
  • , Jessica Thomes-Pepin
  • , Carol Aghajanian
  • , Carolyn McCourt
  • , Ashley Stuckey
  • , Xiaohua Wu
  • , Shin Nishio
  • , Larry J. Copeland
  • , Yvette He
    • Luciana Molinero, Sheetal Patel, Yvonne G. Lin, Victor K. Khor, Kathleen N. Moore

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology